Trial Profile
AA Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2022
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; SAR 439459 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 07 Jun 2022 Results (n=109) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 04 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 29 Nov 2021 Planned End Date changed from 1 May 2023 to 26 Jan 2022.